2026-03-06 01:30Financial Data and Key Metrics Changes - The company reported a revenue of $366 million for the period, reflecting a 26% increase compared to the previous year [1]. Business Line Data and Key Metrics Changes - Specific business line performance details were not provided in the available content, indicating a lack of clarity on individual segment contributions [5]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were mentioned in the provided content [5]. Company Strategy and Development Direction - The company is focusing on first-in-class products and has several NDA submissions planned for 2025 and 2026, indicating a strong pipeline and commitment to innovation [2][4]. Management Comments on Operating Environment and Future Outlook - Management has not provided detailed comments on the operating environment or future outlook in the available content [5]. Other Important Information - The company is involved in various clinical trials and has multiple products in development, including those targeting specific biomarkers [3][4]. Q&A Session Summary Question: What is the guidance for 2026? - The company provided a revenue guidance of $148 million for 2025 and an estimated range of $200 million to $300 million for 2026 [6].